The Effectivity of Anti Tuberculosis Therapy in Idiopathic Uveitis With Positive IGRA
Tuberculous Uveitis
About this trial
This is an interventional treatment trial for Tuberculous Uveitis focused on measuring Tuberculosis, Uveitis, Tuberculous Uveitis, Idiopathic Uveitis, Interferon Gamma Release Assay, Anti Tuberculosis Therapy, IGRA, ATT
Eligibility Criteria
Inclusion Criteria:
- Patient that is newly diagnosed with uveitis of unknown origin/idiopathic (as evidenced by a series of uveitis work-up tests) and tested positive for IGRA (>0.35 U/ml).
- Age >18 years old
- Lives in Jakarta/Bogor/Depok/Tangerang/Bekasi area or willing to participate in research until the end of monitoring program
- Willing to participate in the research and sign the informed consent after receiving explanation regarding the research
Exclusion Criteria:
- Patients with positive aqueous tap examination results on one of the examination panels for the bacteria causing infectious uveitis according to the standard examination
- Anterior uveitis patient with a positive HLA-B27 test result
- The patient is proven to have active TB or lives in the same house with an active TB patient
- Patients are included in the TB reactivation risk index group according to the 2018 WHO LTBI (Latent Tuberculosis Incident) Guideline
- HIV positive patient
- Patients with uveitis sanata at the first visit
- Patients with visual acuity less than 1/300 or showing signs of preptisis based on ophthalmological examination and ultrasound of the eye
- The patient has a history of previous ATT consumption
- Patients with impaired liver function or other systemic conditions which according to the Internal Medicine Department are not eligible to receive ATT
- The patient has a history of taking antibiotics in the last 1-2 weeks
- The patient is not willing to sign the informed consent
- The patient was pregnant at the first visit or was planning to become pregnant during the study period
Sites / Locations
- Cipto Mangunkusumo National Central General Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Anti Tuberculosis Therapy
Oral Steroid
Dosage form: ATT fixed-dose combination (FDC). FDC intensive phase containing 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol), while FDC continuation phase containing rifampicin-isoniazid. Dosage: according to body weight, 30-37 kg: 2 tablets, 38-54 kg: 3 tablets, 55-70 kg: 4 tablets, more than 70 kg: 5 tablets. Frequency: Intensive phase: once daily. Continuation phase: 3 times/week. Duration: 6 months (2 months of FDC intensive phase + 4 months of FDC continuation phase)
Dosage form: Oral prednisone Dosage: 1 mg/kgBW/day (max 60 mg/day) Duration: until the uveitis is controlled or up to 4 weeks of administration, after that the dose will be tappered off gradually.